Grant RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Effects of Rm-493, a Melanocortin
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy & Safety Ofgs-6624
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Gs
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Parallel Group Study to Evaluate the . . .
- A Phase 2, Randomized, Open-Label Study of the Safety, Antiviral Activity, and Pharmacokinetics of HCV-796 administered in combination with Peginterferon alfa-2b (PEG-Intron), with or without concomitant ribavirin (REBETOL), versus PEG-Intron plus REBETOL in subjects with hepatitis C virus genotype 1 infection
- A Phase 2, Randomized, Open-Label Study of the Safety, Antiviral Activity, and Pharmacokinetics.....
- A Phase 2... Efficacy & Tolerability of Subcutaneously (Sc) Administered Ravpal-Peg in Patients With Pku for 24 Weeks.
- A Phase 2/3 Mulitcenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golim
- A Phase 2/3 Multicenter, Open Label, Multicohort, Two Part Study Evaluating the Pharmacokinetics(Pk) Safety And........
- A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of Pegylated Recombinant Factor
- A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety and Antiviral Activity of the Elvitegravir/Cobicistat
- A Phase 2a Randomized Double Blind Placebo Controlled Multicenter Study to Evaluate the Safety and Efficacy of Intraveno
- A Phase 2a, Multi-Center Randomized Double-Blind Placebo Controlled Single Ascending Dose Study to Investigate..........
- A Phase 2a, randomized, double blind, placebo controlled, multi-center study to evaluate the safety and efficacy of intravenous infusion of Human Placenta-Derived Cells (PDA001) for the treatment of adults with moderate-tosevere Crohn's disease
- A Phase 2B Multi Center Randomized Double Blind Parallel Group Placebo Controlled Dose Ranging Study Comparing the ....
- A Phase 2B Multi-Center Randomized Placebo-Controlled Dose- Ranging Staudy to Investigate the Safety & Tolerability...
- A Phase 2B Multicenter Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy And.....
- A Phase 2B Study of Bms-790052 in Combinatin With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1
- A Phase 2B Study of BMS-790052 in Combination with Peg interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment with Peg interferon Alfa plus Ribavirin Therapy
- A Phase 2b Study of BMS-790052 in Combination with Peg- Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C
- A Phase 2B Study of Bms-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive . .
- A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and
- A Phase 2B, Randomized Double-blind Placebo Controlled Safety and Efficacy Trial of Multiple Dosing Regiments Of...
- A Phase 2B, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With At-100
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peg interferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 or 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peg interferon Alfa 2a (PEG, Pegasys®), and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peg interferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peg interferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
- A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of Abt
- A Phase 2B/3, Multi-Center Rndmz, Dbl-Bld, Placebo Controlled Trial to Evaluate the Safety & Efficacy of Pagibaximab Inj